NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

Sophiris Bio Inc (NASDAQ:SPHS) released its quarterly earnings results on Friday, November, 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). View Sophiris Bio's Earnings History.

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Sophiris Bio.

3 analysts have issued 1-year price objectives for Sophiris Bio's stock. Their forecasts range from $2.80 to $6.00. On average, they expect Sophiris Bio's share price to reach $4.60 in the next year. This suggests a possible upside of 497.4% from the stock's current price. View Analyst Price Targets for Sophiris Bio.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.

News articles about SPHS stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sophiris Bio earned a news sentiment score of 3.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for Sophiris Bio.

Some companies that are related to Sophiris Bio include CV Sciences (CVSI), Oncolytics Biotech (ONCY), Vaccinex (VCNX), Cyclerion Therapeutics (CYCN), Otonomy (OTIC), Aquestive Therapeutics (AQST), Stealth BioTherapeutics (MITO), Enlivex Therapeutics (ENLV), TFF Pharmaceuticals (TFFP), Sesen Bio (SESN), Oramed Pharmaceuticals (ORMP), Axovant Gene Therapies (AXGT), IMMUTEP LTD/S (IMMP), Proteostasis Therapeutics (PTI) and Trevi Therapeutics (TRVI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), Celator Pharmaceuticals (CPXX), SLS International (SLS), Heat Biologics (HTBX), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Verastem (VSTM), Novavax (NVAX) and Rigel Pharmaceuticals (RIGL).

Sophiris Bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.26%). View Institutional Ownership Trends for Sophiris Bio.

SPHS stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Sophiris Bio.

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPHS stock can currently be purchased for approximately $0.77.

Sophiris Bio has a market capitalization of $26.54 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.

The official website for Sophiris Bio is http://www.sophirisbio.com/.

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]